Filing Overview
OmniAb, Inc. filed a Form 8-K reporting a board appointment effective November 1, 2023. The filing does not contain quarterly or annual financial results.
Business Context and Reporting Period
OmniAb is a Delaware corporation headquartered in Emeryville, California, with common stock trading under OABI and warrants under OABIW. The reported event occurred on November 1, 2023.
Material Changes
- Steven Love was appointed to the Board of Directors.
- Mr. Love was appointed Chair of the Audit Committee and a member of the Human Capital Management and Compensation Committee.
- The Board determined that Mr. Love is independent under Nasdaq listing rules.
- Mr. Love has served as Chief Financial Officer of Heap Inc. since September 2021 and has prior CFO experience at several SaaS and technology companies, as well as finance experience at publicly traded biotechnology and pharmaceutical companies.
Compensation and Other Terms
- Mr. Love received restricted stock units representing 40,000 shares of common stock and options to purchase 80,000 shares.
- The options have an exercise price equal to the fair market value of the common stock on the grant date.
- The equity awards vest in three equal annual installments over the first three anniversaries of the grant date.
- He will receive cash compensation under the Company’s director compensation and stock ownership policy and entered into the Company’s standard indemnification agreement.
- The filing states there are no arrangements or understandings supporting his selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Financial Metrics, Outlook, and Risks
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, operating outlook, contingencies, or other financial metrics. It does not identify unusual financial items or material business risks beyond the governance and compensation matters described above.
Investor Verification Items
- Confirm the grant-date fair value, vesting commencement date, and accounting treatment of the restricted stock units and options.
- Review subsequent filings for changes in Board committee composition or Mr. Love’s service status.
- Review the Company’s director compensation policy and latest Form 10-K for the applicable cash compensation and indemnification terms.
- Assess any future dilution from the 40,000 restricted stock units and 80,000 stock options.